* subject infected with hcv (hcv antibody positive), hbv (hbsag positive), hiv (hiv antibody positive), or htlv (htlv antibody positive). * subject is albumin-intolerant. * subject with life expectancy less than 4 weeks. * subject participated in other investigational somatic cell therapies within past 30 days. * subject with positive pregnancy test result. * researchers consider unsuitable.

* subject infected with hcv (hcv antibody positive), hbv (hbsag positive), hiv (hiv antibody positive), or htlv (htlv antibody positive). * subject is albumin-intolerant. * subject with life expectancy less than 4 weeks. * subject participated in other investigational somatic cell therapies within past 30 days. * subject with positive pregnancy test result. * researchers consider unsuitable.

- subject infected with hcv (hcv antibody positive), hbv (hbsag positive), hiv (hiv antibody positive), or htlv (htlv antibody positive). - subject is albumin-intolerant. - subject with life expectancy less than 4 weeks. - subject participated in other investigational somatic cell therapies within past 30 days. - subject with positive pregnancy test result. - researchers consider unsuitable.

- subject infected with hcv (hcv antibody positive), hbv (hbsag positive), hiv (hiv antibody positive), or htlv (htlv antibody positive). - subject is albumin-intolerant. - subject with life expectancy less than 4 weeks. - subject participated in other investigational somatic cell therapies within past 30 days. - subject with positive pregnancy test result. - researchers consider unsuitable.